(5-溴-2,3-二氢苯并呋喃-2-基)甲醇 | 197577-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: (5-溴-2,3-二氢苯并呋喃-2-基)甲醇
• 英文名称: 5-bromo-2-hydroxymethyl-2,3-dihydrobenzo[b]furan
• 英文别名: (5-bromo-2,3-dihydrobenzofuran-2-yl)methanol；(5-bromo-2,3-dihydro-1-benzofuran-2-yl)methanol
• CAS: 197577-35-8
• 化学式: C₉H₉BrO₂
• mdl: MFCD16037374
• 分子量: 229.073
• InChiKey: COPLPYBSTHRUPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-溴-2,3-二氢苯并呋喃-2-基)甲醇 在 氯化亚砜 、 jones' reagent 、 氨 、 sodium methylate 、 phosphorus pentoxide 作用下， 以 1,4-二氧六环 、 丙酮 、 甲苯 、 苯 为溶剂， 反应 56.75h， 生成 2-(5-Bromo-2,3-dihydro-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003
• 作为产物：
  描述：

  2-烯丙基-4-溴苯酚 在 甲烷磺酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 (5-溴-2,3-二氢苯并呋喃-2-基)甲醇
  参考文献：
  名称：

  叠氮基取代的芳基硼酸：合成和铃木-宫浦交叉偶联反应

  摘要：

  由相应的叠氮基取代的芳基溴化物通过锂化和用硼酸三烷基酯处理来制备具有较远叠氮基的芳基硼酸。当起始的芳基溴化物具有邻烷氧基时，可以稳定中间芳基锂物质，从而获得了制备产率。芳基硼酸的常规Suzuki交叉偶联通常在保留叠氮基团的情况下进行得很好。但是，叠氮甲基片段有时会发生氧化转化为腈。

  DOI：

  10.1016/j.tet.2005.12.026

文献信息

• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
  申请人：——

  公开号：US20030195352A1

  公开（公告）日：2003-10-16

  This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.

  这项发明涉及新型苯并呋喃和二氢苯并呋喃化合物，含有这些化合物的药物组合物，以及使用这些组合物治疗β-3肾上腺素受体介导的疾病的方法。
• Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Neustadt R. Bernard

  公开号：US20050239795A1

  公开（公告）日：2005-10-27

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药学上可接受的盐的化合物，其中R是可选择地取代的苯基、呋喃基、噻吩基、吡啶基、吡啶N-氧化物基、噁唑基或吡咯基，或环烯基R1、R2、R3、R4和R5为H、烷基或烷氧基烷基；Z是可选择地取代的芳基或杂芳基。还公开了公式I化合物在治疗中枢神经系统疾病，特别是帕金森病中的用途，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• [EN] PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS<br/>[FR] DÉRIVÉS DE PYRAZOLYLE UTILES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：NOVARTIS AG

  公开号：WO2021124222A1

  公开（公告）日：2021-06-24

  The present application provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; method for manufacturing said compound, and its therapeutic uses. The present application further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

  本申请提供了化合物的公式(I)或其立体异构体，或其对映异构体，或其可接受的药物盐，或其对映异构体的可接受的药物盐，或其对映异构体的可接受的药物盐；制造该化合物的方法及其治疗用途。本申请还提供了药理活性剂的组合以及包含该化合物的药物组合物。
• One-Step Transformation of 2- or 3-(1-Hydroxyalkyl)-2,3-dihydrobenzofurans to the Acylbenzofurans with N-Bromosuccinimide
  作者：Masashi Ogawa、Hideaki Suzuki、Hideyuki Tsutsui、Atsuyuki Kano、Satoru Katoh、Tadashi Morita、Kiyoshi Matsuda、Norihiro Iibuchi

  DOI：10.3987/com-97-7863

  日期：——